3 Prescription Brand Leader, Surfactant Maker and Rice Exporter Stocks With a Strong Future Roadmap: Mankind Pharma, Galaxy Surfactants and LT Foods
- October 19, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Mankind Pharma Rs 2,275.50, P/E 47.91. Galaxy Surfactants Rs 2,502.00, P/E 24.09. LT Foods Rs 417.65, P/E 21.98. Closing prices of 14 Oct 2026.
Quick Answer
Prescription brand leader, surfactant maker and rice exporter stocks with the clearest long-term roadmaps today include Mankind Pharma in branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, Galaxy Surfactants in surfactants and specialty ingredients for personal care and home care brands and LT Foods in basmati rice and packaged foods sold under brands such as Daawat. FY26 revenue growth was 14.8% at Mankind Pharma, 24.2% at Galaxy Surfactants and 25.7% at LT Foods. P/E stands at 47.91 for Mankind Pharma (industry 37.59), 24.09 for Galaxy Surfactants (industry 36.60) and 21.98 for LT Foods (industry 34.85). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Prescription brand leader, surfactant maker and rice exporter stocks give investors exposure to medicines, personal care ingredients and staple foods bought every day. Volumes, pricing and margins decide how much of that demand turns into profit.
Readers comparing prescription brand leader, surfactant maker and rice exporter stocks should weigh growth, margins, cash flow and valuation together instead of leaning on any single number.
This list covers three prescription brand leader, surfactant maker and rice exporter stocks: Mankind Pharma for branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, Galaxy Surfactants for surfactants and specialty ingredients for personal care and home care brands and LT Foods for basmati rice and packaged foods sold under brands such as Daawat. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Prescription Brand Leader, Surfactant Maker and Rice Exporter Stocks?
Prescription brand leader, surfactant maker and rice exporter stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Prescription Brand Leader, Surfactant Maker and Rice Exporter Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three prescription brand leader, surfactant maker and rice exporter stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Mankind Pharma | 2,275.50 | 99,065 | 47.91 | 37.59 | 11.74% | 0.39 |
| Galaxy Surfactants | 2,502.00 | 8,524 | 24.09 | 36.60 | 9.74% | 0.09 |
| LT Foods | 417.65 | 14,072 | 21.98 | 34.85 | 13.83% | 0.36 |
Among healthcare, chemicals and consumer stocks, Mankind Pharma trades at a premium to the industry P/E, while Galaxy Surfactants and LT Foods trade at a discount.
Why Do Prescription Brand Leader, Surfactant Maker and Rice Exporter Stocks Have a Strong Roadmap in India?
Prescription brand leader, surfactant maker and rice exporter stocks have a strong roadmap in India because prescription demand, personal care brand volumes and branded rice sales keep adding volumes for these firms. Three drivers stand out.
- Medicine demand: Doctors prescribe branded formulations across therapies.
- Personal care: Brands buy surfactants for soaps and shampoos.
- Staple foods: Families buy branded basmati and packaged foods.
Mankind Pharma: Branded Formulations Anchor the Roadmap
Mankind Pharma’s roadmap rests on branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, with a broad brand portfolio supporting prescriptions and sales.
Revenue grew from Rs 7,977.58 crore in FY22 to Rs 14,636.43 crore in FY26, an 83.5% rise, and FY26 revenue was 14.8% higher than FY25. FY26 net profit was Rs 1,938.10 crore. In Q1 FY27, revenue grew 11.7% to Rs 4,075.59 crore, and net profit rose 29.1% to Rs 574.09 crore. Operating margin was 27.06% in FY26 and 27.42% in Q1 FY27 against 26.04% a year earlier.
Debt to equity is 0.39 and return on equity is 11.74%. FY26 operating cash flow was Rs 3,121.29 crore against capital expenditure of Rs 737.24 crore. Mankind Pharma paid a dividend of Rs 1 per share for FY26, a yield of 0.04%. At a P/E of 47.91 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: Q1 FY27 operating margin was 27.42% against 27.06% for FY26, so margin stability is the figure to follow as volumes grow.
Galaxy Surfactants: Personal Care Ingredients Anchor the Roadmap
Galaxy Surfactants’ roadmap rests on surfactants and specialty ingredients for personal care and home care brands, with global consumer companies as customers supporting volumes.
Revenue grew from Rs 3,698.22 crore in FY22 to Rs 5,279.92 crore in FY26, a 42.8% rise, and FY26 revenue was 24.2% higher than FY25. FY26 net profit was Rs 267.38 crore. In Q1 FY27, revenue grew 38.5% to Rs 1,785.18 crore. Operating margin was 9.25% in FY26 and 14.17% in Q1 FY27 against 10.57% a year earlier.
Debt to equity is 0.09 and return on equity is 9.74%. FY26 operating cash flow was Rs 332.66 crore against capital expenditure of Rs 136.95 crore. Galaxy Surfactants paid a dividend of Rs 22 per share for FY26, a yield of 0.91%. At a P/E of 24.09 against an industry P/E of 36.60, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 14.17% against 9.25% for FY26, so margin stability is the figure to follow as volumes grow.
LT Foods: Basmati and Packaged Foods Anchor the Roadmap
LT Foods’ roadmap rests on basmati rice and packaged foods sold under brands such as Daawat, with exports and branded sales supporting revenue.
Revenue grew from Rs 5,450.58 crore in FY22 to Rs 11,023.06 crore in FY26, a 102.2% rise, and FY26 revenue was 25.7% higher than FY25. FY26 net profit rose 2.2% to Rs 625.38 crore. Over four years, net profit rose from Rs 309.20 crore in FY22 to Rs 625.38 crore. In Q1 FY27, revenue grew 26.4% to Rs 3,161.29 crore, and net profit rose 8.9% to Rs 183.45 crore. Operating margin was 11.35% in FY26.
Debt to equity is 0.36 and return on equity is 13.83%. FY26 operating cash flow was Rs 910.50 crore against capital expenditure of Rs 359.62 crore. LT Foods paid a dividend of Rs 3 per share for FY26, a yield of 0.74%. At a P/E of 21.98 against an industry P/E of 34.85, the stock trades below its industry multiple.
What to watch: The P/E of 21.98 against an industry P/E of 34.85 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Best Prescription Brand Leader, Surfactant Maker and Rice Exporter Stocks in India: Mankind Pharma vs Galaxy Surfactants vs LT Foods on Key Financials
Among the best prescription brand leader, surfactant maker and rice exporter stocks in India, Mankind Pharma leads on FY26 operating margin; Galaxy Surfactants leads on Q1 FY27 revenue growth and the lowest debt to equity; LT Foods leads on FY26 revenue growth and return on equity. The table puts the numbers side by side.
| Metric | Mankind Pharma | Galaxy Surfactants | LT Foods |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 14,636.43 | 5,279.92 | 11,023.06 |
| FY26 revenue growth | 14.8% | 24.2% | 25.7% |
| FY26 net profit (Rs Cr) | 1,938.10 | 267.38 | 625.38 |
| FY26 operating profit margin | 27.06% | 9.25% | 11.35% |
| Q1 FY27 revenue growth (YoY) | 11.7% | 38.5% | 26.4% |
| Return on equity | 11.74% | 9.74% | 13.83% |
| P/E ratio | 47.91 | 24.09 | 21.98 |
| Debt to equity | 0.39 | 0.09 | 0.36 |
| Dividend yield | 0.04% | 0.91% | 0.74% |
| FY26 operating cash flow (Rs Cr) | 3,121.29 | 332.66 | 910.50 |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Prescription Brand Leader, Surfactant Maker and Rice Exporter Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen prescription brand leader, surfactant maker and rice exporter stocks and shortlist prescription brand leader, surfactant maker and rice exporter stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Prescription Brand Leader, Surfactant Maker and Rice Exporter Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Mankind Pharma, Galaxy Surfactants and LT Foods live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare, chemicals and consumer stocks cover medicines, surfactants and basmati rice. Mankind Pharma leads on FY26 operating margin; Galaxy Surfactants leads on Q1 FY27 revenue growth and the lowest debt to equity; LT Foods leads on FY26 revenue growth and return on equity.
Across prescription brand leader, surfactant maker and rice exporter stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the prescription brand leader, surfactant maker and rice exporter stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Prescription Brand Leader, Surfactant Maker and Rice Exporter Stocks
Which are the best prescription brand leader, surfactant maker and rice exporter stocks in India with a strong roadmap?
Ans. Mankind Pharma, Galaxy Surfactants and LT Foods stand out for their roadmaps in medicines, surfactants and basmati rice. FY26 revenue growth was 14.8% at Mankind Pharma, 24.2% at Galaxy Surfactants and 25.7% at LT Foods, and return on equity ranges from 9.74% to 13.83%.
Is Mankind Pharma a good stock to buy now?
Ans. Mankind Pharma has a debt to equity ratio of 0.39, a return on equity of 11.74% and a P/E of 47.91 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Mankind Pharma, Galaxy Surfactants and LT Foods?
Ans. The P/E ratio is 47.91 for Mankind Pharma (industry 37.59), 24.09 for Galaxy Surfactants (industry 36.60) and 21.98 for LT Foods (industry 34.85). Only Mankind Pharma trades at or above the industry multiple.
Which of these prescription brand leader, surfactant maker and rice exporter stocks has the highest return on equity?
Ans. LT Foods has the highest return on equity at 13.83%, followed by Mankind Pharma at 11.74% and Galaxy Surfactants at 9.74%.
What are the risks of investing in prescription brand leader, surfactant maker and rice exporter stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did Mankind Pharma, Galaxy Surfactants and LT Foods perform in Q1 FY27?
Ans. Mankind Pharma reported revenue of Rs 4,075.59 crore, up 11.7% year on year, and net profit rose 29.1% to Rs 574.09 crore. Galaxy Surfactants reported revenue of Rs 1,785.18 crore, up 38.5% year on year. LT Foods reported revenue of Rs 3,161.29 crore, up 26.4% year on year, and net profit rose 8.9% to Rs 183.45 crore.
Do prescription brand leader, surfactant maker and rice exporter stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 0.04% for Mankind Pharma, 0.91% for Galaxy Surfactants and 0.74% for LT Foods, based on dividends declared for FY26.
How can I invest in prescription brand leader, surfactant maker and rice exporter stocks in India?
Ans. You can buy prescription brand leader, surfactant maker and rice exporter stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.